Revenue Estimates Analysis: UDR, Inc.(NYSE:UDR): The Medicines Company(NASDAQ:MDCO)

0
6

UDR, Inc. (UDR) will report its next earnings on Apr 30 AMC. The company reported the earnings of $0.3/Share in the last quarter where the estimated EPS by analysts was $0.09/share. The difference between the expected and actual EPS was $0.21/share, which represents an Earnings surprise of 233.3%.

Many analysts are providing their Estimated Earnings analysis for UDR, Inc. and for the current quarter 6 analysts have projected that the stock could give an Average Earnings estimate of $0.08/share. These analysts have also projected a Low Estimate of $0.07/share and a High Estimate of $0.13/share.

In case of Revenue Estimates, 16 analysts have provided their consensus Average Revenue Estimates for UDR, Inc. as 267.79 Million. According to these analysts, the Low Revenue Estimate for UDR, Inc. is 265.2 Million and the High Revenue Estimate is 273.82 Million. The company had Year Ago Sales of 250.48 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for UDR to be 6.4%. They are projecting Next Quarter growth of 6.12%. For the next 5 years, UDR, Inc. is expecting Growth of 4.28% per annum, whereas in the past 5 years the growth was 5.1% per annum.

Some buy side analysts are also providing their Analysis on UDR, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for UDR, Inc. might touch $52 high while the Average Price Target and Low price Target is $45.26 and $39 respectively.

UDR, Inc. closed its last trading session at $45.48 with the gain of 0.7%. The Market Capitalization of the company stands at 12.82 Billion. The Company has 52-week high of $45.84 and 52-week low of $34.48. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.27% where SMA50 and SMA200 are 2.21% and 11.66% respectively. The Company Touched its 52-Week High on 04/03/19 and 52-Week Low on 05/18/18.

The Relative Volume of the company is 1.02 and Average Volume (3 months) is 1.47 million. The company’s P/E (price to earnings) ratio is 62.14 and Forward P/E ratio of 100.66.

The company shows its Return on Assets (ROA) value of 2.6%. The Return on Equity (ROE) value stands at 7.3%. While it’s Return on Investment (ROI) value is 5.5%.

While looking at the Stock’s Performance, UDR, Inc. currently shows a Weekly Performance of 0.39%, where Monthly Performance is 1.04%, Quarterly performance is 14.07%, 6 Months performance is 15.31% and yearly performance percentage is 29.89%. Year to Date performance value (YTD perf) value is 15.6%. The Stock currently has a Weekly Volatility of 1.07% and Monthly Volatility of 1.27%.

The Medicines Company (MDCO) will report its next earnings on Feb 27 BMO. The company reported the earnings of $-0.62/Share in the last quarter where the estimated EPS by analysts was $-0.61/share. The difference between the expected and actual EPS was $-0.01/share, which represents an Earnings surprise of -1.6%.

Many analysts are providing their Estimated Earnings analysis for The Medicines Company and for the current quarter 6 analysts have projected that the stock could give an Average Earnings estimate of $-0.62/share. These analysts have also projected a Low Estimate of $-0.85/share and a High Estimate of $-0.29/share.

These analysts also forecasted Growth Estimates for the Current Quarter for MDCO to be 15.8%. They are projecting Next Quarter growth of 0%. For the next 5 years, The Medicines Company is expecting Growth of 14.96% per annum, whereas in the past 5 years the growth was 17.28% per annum.

Some buy side analysts are also providing their Analysis on The Medicines Company, where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for The Medicines Company might touch $85 high while the Average Price Target and Low price Target is $51.5 and $25 respectively.

The Medicines Company closed its last trading session at $27.8 with the gain of 1.62%. The Market Capitalization of the company stands at 2.06 Billion. The Company has 52-week high of $41.57 and 52-week low of $16.69. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.03% where SMA50 and SMA200 are 8.63% and -0.52% respectively. The Company Touched its 52-Week High on 07/17/18 and 52-Week Low on 12/21/18.

The Relative Volume of the company is 0.75 and Average Volume (3 months) is 1.05 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -15.2%. The Return on Equity (ROE) value stands at 0%. While it’s Return on Investment (ROI) value is -18.2%.

While looking at the Stock’s Performance, The Medicines Company currently shows a Weekly Performance of -4.46%, where Monthly Performance is 7.87%, Quarterly performance is 43.11%, 6 Months performance is 4.59% and yearly performance percentage is -7.62%. Year to Date performance value (YTD perf) value is 47.6%. The Stock currently has a Weekly Volatility of 3.51% and Monthly Volatility of 3.87%.

SHARE